Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Hcv ns3 protease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
HCV NS3 protease is a 180-amino acid chymotrypsin-like serine protease. Its function is the auto-proteolytic cleavage of HCV viral polyprotein (~3000 aa) into individual, non-structural (NS) proteins with various functions. Thus it is an essential component of HCV replication and infectivity.
Hepatitis C inhibitor tri-peptides
ActiveUS7091184B2Better pharmacokinetic profileNot significant inhibitory activityBiocideDipeptide ingredientsHcv ns3 proteaseHepatitis C
Compounds of formula (I):wherein R1 is hydroxyl or sulfonamide derivative; R2 is t-butyl or —CH2—C(CH3)3 or —CH2-cyclopentyl; R3 is t-butyl or cyclohexyl and R4 is cyclobutyl, cyclopentyl or cyclohexyl; or a pharmaceutically acceptable salt thereof, are described as useful as inhibitor of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Macrocyclic peptides active against the hepatitis C virus
ActiveUS20050080005A1Avoid virus infectionBiocideTripeptide ingredientsMacrocyclic peptideHcv ns3 protease
Compounds of formula I: wherein D, R4, R3, L0, L1, L2, R2 and Rc are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Macrocyclic peptides active against the hepatitis C virus
ActiveUS20050192212A1Inhibition of replicationEffective treatmentBiocideAntiviralsMacrocyclic peptideHcv ns3 protease
Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Hepatitis C inhibitor compounds
Owner:BOEHRINGER INGELHEIM INT GMBH
Hepatitis C inhibitor compound
Compounds of formula (I): wherein B, X, R3, R21, R22, R1 and Rc are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Hepatitis C inhibitor peptide analogs
Compounds of formula (I): wherein R1, R2, R3, R4, R5, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
Owner:VERTEX PHARMA INC
Macrocyclic peptides active against the hepatitis C virus
InactiveUS20050075279A1Not significant inhibitory activityImprove stabilityBiocideDigestive systemMacrocyclic peptideAryl
Compounds of formula (I): wherein R1 is (C1-8)alkyl, (C3-7)cycloalkyl, {(C1-6)alkyl-(C3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1 is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof, useful as an inhibitor of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Hepatitis C inhibitor dipeptide analogs
ActiveUS20060046965A1Not significant inhibitory activityBiocideDipeptide ingredientsDipeptideHcv ns3 protease
Compounds of formula (I): wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Peptide substrates for HCV NS3 protease assays
InactiveUS6251583B1SsRNA viruses positive-sensePeptide/protein ingredientsPeptide substrateFluorescence
Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.
Owner:MERCK SHARP & DOHME CORP
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
Owner:VERTEX PHARMA INC
Hepatitis C Inhibitor Compounds
Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
Owner:BOEHRINGER INGELHEIM INT GMBH
Macrocyclic peptides active against the hepatitis C virus
Compounds of formula I:wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O(C1-6)alkyl, amido, amino or phenyl; R2 is (C5-6)cycloalkyl and R3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM CANADA LTD
Hepatitis c inhibitor peptide analogs
The invention relates to compounds of formula (I) wherein R′, R2, R3, R4, R5, R6, Y, n and m are as defined (herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).
Owner:BOEHRINGER INGELHEIM INT GMBH
HCV NS3 Protease Inhibitors
InactiveUS20100099695A1Likelihood of moreSeverity of moreBiocideTripeptide ingredientsEnzyme Inhibitor AgentHcv hepatitis c virus
Owner:MERCK SHARP & DOHME CORP +1
Macrocyclic peptides active against the hepatitis C virus
ActiveUS20060089300A1Not significant inhibitory activityBiocideDigestive systemMacrocyclic peptideAryl
Compounds of formula (I): wherein R1 is (C1-8)alkyl, (C3-7)cycloalkyl, {(C1-6)alkyl-(C3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1 is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof, useful as an inhibitor of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Lactam inhibitors of Hepatitis C virus NS3 protease
The present invention relates to lactams of Formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Owner:BRISTOL MYERS SQUIBB CO
Hcv ns3 protease inhibitors
ActiveUS20140296136A1Likelihood of moreSeverity of moreOrganic active ingredientsTripeptide ingredientsEnzyme Inhibitor AgentHcv hepatitis c virus
Owner:MERCK SHARP & DOHME LLC +2
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
Owner:VERTEX PHARMA INC
Hepatitis C inhibitor compounds
Compounds of formula (I):wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
Owner:BOEHRINGER INGELHEIM INT GMBH
Macrocyclic peptides active against the hepatitis C virus
Compounds of formula I:wherein D, R4, R3, L0, L1, L2, R2 and RC are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
Hepatitis C Inhibitor Peptide Analogs
The compounds of formula I wherein R1, R2, R3, R4 and R5 are defined herein, are useful as inhibitors of the hepatitis C virus NS3 protease The invention further relates to azalactone compounds of the formula (II) which can be reacted with an amide anion to produce the HCV NS3 protease inhibitors of formula (I)
Owner:BAILEY MURRAY D +3
Inhibitors of Hepatitis C NS3 Protease
InactiveUS20100087382A1Potent activityAvoid specificityDigestive systemInactivation/attenuationHcv ns3 proteaseCombinatorial chemistry
Compounds of formula I:wherein R1, R2, R2a, R3, R4 and R5 are defined herein, are useful as inhibitors of the HCV NS3 protease.
Owner:BOEHRINGER INGELHEIM INT GMBH
HCV NS3 protease inhibitors
ActiveUS8461107B2Likelihood of moreSeverity of moreBiocidePeptide/protein ingredientsMedicineHcv ns3 protease
Owner:MERCK SHARP & DOHME LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com